Lupin announces US FDA approval and launch of Sugammadex injection
Global pharma major Lupin announced that following approval from the United States Food and Drug Administration (US FDA) for its Abbreviated New Drug Application, the company launched Sugammadex Injection, 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vial in the United States.
Lupin’s Sugammadex Injection is the bioequivalent to Bridion Injection of Merck, Sharp & Dohme LLC (Merck) and is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and pediatric patients aged 2 years and older undergoing surgery.
The post Lupin announces US FDA approval and launch of Sugammadex injection appeared first on Express Pharma.
Apa Reaksi Anda?
Suka
0
Kurang Suka
0
Setuju
0
Tidak Setuju
0
Bagus
0
Berguna
0
Hebat
0
Edusehat
Platform Edukasi Online Untuk Komunitas Kesehatan Agar Mendapatkan Informasi Dan Pengetahuan Terbaru Tentang Kesehatan Dari Nasional Maupun Internasional. ||
An online education platform for the health community to obtain the latest information and knowledge about health from both national and international sources.
